Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma

trialsTrialPlanned

Adebrelimab Plus S-1 for Resected Cholangiocarcinoma

A phase 2 trial of adebrelimab and S-1 in gallbladder cancer and other biliary tract cancers, run by Xingjun Guo, not yet recruiting.

Overview Connected8

Overview

Adebrelimab Plus S-1 for Resected Cholangiocarcinoma is a phase 2 interventional study registered as NCT07561775 by Xingjun Guo, with a registry enrolment figure of 40 participants, started 2026-04-21 and due to reach its primary completion in 2028-01-01. Interventions recorded: Adebrelimab, S-1. Conditions listed: Cholangiocarcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.

Setting

A Single-Arm, Exploratory Clinical Study of Adebrelimab Combined With S-1 in Patients With Resected Cholangiocarcinoma

Phase

Phase 2

Sponsor

Xingjun Guo

Registry

Started

2026-04-21 (estimated)

Enrolled

40 enrolled

Connected

Similar pages

Trial
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
Shares Adebrelimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Trial
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Shares Adebrelimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Trial
A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
Shares Adebrelimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Trial
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies
Shares Adebrelimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Trial
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Shares Tegafur, gimeracil and oteracil (S-1), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Trial
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
Shares Tegafur, gimeracil and oteracil (S-1), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Trial
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
Shares Adebrelimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Trial
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
Shares Tegafur, gimeracil and oteracil (S-1), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.

cancers

Biliary tract cancer (all types)Biliary tract cancer (cholangiocarcinoma)Gallbladder cancer

technologies

Cytotoxic chemotherapy Immune checkpoint inhibitors

drugs

ApprovedMonoclonal antibody (anti-PD-L1, humanised IgG4)

Adebrelimab · Arelili

ApprovedOral fluoropyrimidine combination (antimetabolite)

Tegafur, gimeracil and oteracil (S-1) · Teysuno

terms

Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)

Evidence strength28/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
40 enrolled+8
No structured primary endpoint0
Result: planned0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-24 · Jude Gomila · Gallbladder cancer treatments and trials · diff · file

Sources & links

ClinicalTrials.gov NCT07561775

gallbladder-deep-dive

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Gallbladder cancer
Biliary tract cancer (cholangiocarcinoma)
Biliary tract cancer (all types)

Technologies

Immune checkpoint inhibitors
Cytotoxic chemotherapy

Products

Adebrelimab
Tegafur, gimeracil and oteracil (S-1)

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Adebrelimab Plus S-1 for Resected Cholangiocarcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct07561775/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct07561775.

WebMCP tools registered on this page: onco_search, onco_get_entity.